Research programme: transmucosal therapeutics - Endo, Inc. Endo, Inc.
Latest Information Update: 27 Apr 2024
At a glance
- Originator Auxilium Pharmaceuticals
- Developer Endo, Inc.
- Class
- Mechanism of Action
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- No development reported Bladder dysfunction; Pain
Most Recent Events
- 23 Apr 2024 Endo International has been acquired and merged into Endo, Inc.
- 16 Jul 2016 No recent reports of development identified for preclinical development in Bladder-dysfunction in USA (Transmucosal)
- 16 Jul 2016 No recent reports of development identified for preclinical development in Pain in USA (Transmucosal)